{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "NUVL",
  "name": "Nuvalent, Inc.",
  "url": "https://frontierpicks.com/dossiers/NUVL/",
  "json_url": "https://frontierpicks.com/dossiers/NUVL.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Closed, not pending: GSK completed the $124 all-cash acquisition on 2026-07-15 after 91.3% of shares were tendered by the 2026-07-14 expiry; trading was suspended 2026-07-15 and Form 25 delisting requested. No US-listed NUVL equity remains — the narrative is dead and the only residual is takeout read-through to peer resistance-mutant NSCLC names.",
  "invalidation_trigger": "A daily close below $124 on a US venue would signal a failure of the $124 cash payment or the Section 251(h) merger; with completion announced 2026-07-15, trading suspended and Form 25 requested, no NUVL close can print, so the condition cannot be met and the read is closed.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "No US-listed NUVL equity trades: shares were halted after the 2026-07-14 close, suspended pre-open 2026-07-15, and Form 25 delisting was requested.",
    "Consideration is fixed cash of $124/share; untendered shares convert into the right to receive that amount under the Section 251(h) merger.",
    "Nuvalent had a dual-class structure",
    "Zidesamtinib, neladalkib and NVL-330 now sit inside GSK's oncology portfolio; their FDA decision dates are GSK-level events.",
    "Any surviving NUVL-symbol quote is a stub of a deregistering security rather than a continuing Nasdaq listing."
  ],
  "body_markdown": "## Current Thesis\nThe July note said the tender had cleared and the instrument was being retired. It has been. GSK announced completion of the acquisition on 2026-07-15, one day after the offer expired at one minute past 11:59 p.m. 67,083,713 Class A and 5,435,254 Class B, 91.3% of shares outstanding — validly tendered and accepted for payment. Trading was halted after the 2026-07-14 close and suspended before the 2026-07-15 open; Nuvalent asked Nasdaq to file Form 25 to delist and deregister the shares. Aggregate equity value was ~$10.6bn (£8.0bn), ~$9.4bn (£7.1bn) net of cash acquired. There is no narrative leg left to buy, because there is no US-listed security: the life-cycle label is dead, dated to the 2026-07-15 trading suspension. What survives is a comparable — a $124 cash mark on a resistance-mutant NSCLC franchise — while the assets themselves now sit inside GSK.\n\n## Bull Case\n\n- **The Section 251(h) structure removed the last procedural gate.** Crossing the ownership threshold let the back-end merger complete without a stockholder meeting; GSK confirmed completion on 2026-07-15.\n- **The strategic rationale that supported close probability was ratified by the buyer's own disclosure.** GSK's 2026-07-15 release names zidesamtinib (ROS1), neladalkib (ALK) and NVL-330 (phase I, HER2-altered NSCLC) as the acquired assets, with FDA decisions still pending — PDUFA target dates 2026-09-18 and 2026-11-27.\n\n## Bear Case\n- **$124 is the last number this ticker prints.** The consideration is fixed cash; untendered shares convert into the right to receive it. No compounding, no re-rating, no second leg.\n- **No topping bid appeared across the entire 2026-06-24 to 2026-07-14 window.** The six desks that cut to neutral-equivalent ratings between 2026-06-10 and 2026-06-24 all set $124 exactly, and the tape never challenged the number.\n- **The optionality moved to a different issuer.** Whatever the 2026-09-18 zidesamtinib and 2026-11-27 neladalkib decisions prove worth, they accrue to GSK — inside a company where two NSCLC approvals are a line item, not the whole story.\n- **Post-suspension there is nothing to price.** No NUVL close has printed since 2026-07-14; screens still carrying the symbol are showing a deregistering stub.\n\n## Setup & Price Structure\nThe last completed daily close was $123.96 on 2026-07-14 — 0.03% under the $124 consideration and identical to the 52-week high, because the 52-week high is the deal print. The 3-month return of 18.0% is one gap (the 2026-06-24 announcement) followed by three weeks of a flat pin; RSI(14) at 87.1 measures that step function and carries no demand information. Conventional crowding observables do not apply here: no earnings date exists for a deregistering registrant, moving averages describe a price that stopped moving, and insider filings after 2026-07-14 reflect merger conversion rather than discretionary selling. The one positioning observable worth recording is the collapse of analyst dispersion — Bernstein (Market Perform, 2026-06-24), TD Cowen (Hold), Barclays (Equal-Weight), Wedbush, UBS and Guggenheim (all Neutral, 2026-06-10) converged on an identical $124 target, which is coverage pricing a cash number rather than a business.\n\n## Catalyst Calendar (next 30 days)\n- **None for NUVL through 2026-09-15.** No quarterly report, no guidance, no shareholder vote — the Section 251(h) merger dispensed with the vote, and the Form 25 / Form 15 process ends the reporting obligation.\n- **2026-09-18 (outside the 30-day window):** PDUFA target action date for zidesamtinib in TKI pre-treated ROS1-positive NSCLC — now a GSK event.\n- **2026-11-27:** PDUFA target action date for neladalkib (Priority Review) in TKI pre-treated ALK-positive NSCLC — also GSK's.\n- **Ongoing, no fixed date:** residual merger administration — paying-agent disbursement, Form 15 deregistration taking effect, and any Delaware appraisal filings by untendered holders.\n\n## What Would Change Our Mind\nThe dead label rests on plumbing rather than price: completion was announced 2026-07-15, the shares were suspended, and Form 25 was requested. Breaking that read requires evidence the mechanics failed — an 8-K or exchange notice disclosing non-payment, a reversal of the merger, or resumption of NUVL trading on a US venue. Expressed as the gradeable condition: a daily close below $124 would mark a payment or delisting disruption, and no such close can print while the shares are suspended. On the read-through side, the argument that the $124 / ~$10.6bn mark reset takeout expectations for resistance-mutant NSCLC peers weakens if the 2026-09-18 zidesamtinib decision returns a complete response letter or a materially narrowed label, since the premium GSK paid was underwritten on those approvals landing.\n\n## Correlation Notes\n- NUVL has no live correlation to anything — no prints since the 2026-07-14 close, trading suspended 2026-07-15.\n- The live analogue is GSK: the acquired assets sit in its oncology portfolio at ~$9.4bn net of cash acquired, against FDA dates 2026-09-18 and 2026-11-27.\n- For biotech M&A comps the closed transaction supplies a dated mark: ~$10.6bn equity value, $124 reported at roughly a 40% premium to the pre-announcement close, offer commenced 2026-06-24 and completion announced 2026-07-15.\n- Read-through candidates are clinical-stage precision-oncology names with resistance-mutation franchises and near-term NDA optionality; the operative fact for that group is that a large-cap paid a full premium for pre-approval assets, which is a sector-level datapoint and not a NUVL one.",
  "first_seen": "2026-07-02",
  "last_analyzed": "2026-08-16T11:40:32+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}